

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 02/10/2012

ClinicalTrials.gov ID: NCT00391872

Study Identification

Unique Protocol ID: D5130C05262

Brief Title: A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO)

Official Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]

Secondary IDs: PLATO

Study Status

Record Verification: February 2012

Overall Status: Completed

Study Start: October 2006

Primary Completion: March 2009 [Actual]

Study Completion: March 2009 [Actual]

Sponsor/Collaborators

Sponsor: AstraZeneca

Responsible Party: Sponsor

Collaborators:

Oversight

FDA Regulated?: Yes

Applicable Trial?: Section 801 Clinical Trial? Yes
Delayed Posting? No

IND/IDE Protocol?: Yes

IND/IDE Information: Grantor: CDER
IND/IDE Number: 65,808
Serial Number: 118
Has Expanded Access? No

Review Board: Approval Status:
Board Name:
Board Affiliation:
Phone:
Email:

Data Monitoring?:

Plan to Share Data?:

Oversight Authorities: United States: Food and Drug Administration

Study Description

Brief Summary: Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.

Detailed Description:

Conditions

Conditions: Acute Coronary Syndrome

Keywords: ACS
Acute coronary syndrome
Heart attack
Unstable angina
Coronary artery disease

Study Design

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: Phase 3

Intervention Model: Parallel Assignment

Number of Arms: 2

Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Allocation: Randomized

Endpoint Classification: Safety/Efficacy Study

Enrollment: 18624 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Active Comparator: Clopidogrel Oral treatment	Drug: Clopidogrel Clopidogrel 75 mg once daily dose (ODD) Other Names: <ul style="list-style-type: none">• Plavix®
Experimental: Ticagrelor Oral treatment	Drug: Ticagrelor Ticagrelor (AZD6140) 90 mg twice daily dose (BD) Other Names: <ul style="list-style-type: none">• AZD6140

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 18 Years

Maximum Age:

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Male or female 18 years or older who has been hospitalised for chest pain and potential ACS
- Females of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception

Exclusion Criteria:

- Persons with moderate or severe liver disease
- Persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS
- Persons who are being treated with blood clotting agents that cannot be stopped

Contacts/Locations

Study Officials: Robert Harrington, MD
Study Principal Investigator
Duke Clinical Research Institute

Lars Wallentin, MD
Study Principal Investigator
Uppsala Clinical Research Centre

Jonathan C. Fox, MD
Study Director
AstraZeneca

Locations: Argentina
Research Site
Adroque, Buenos Aires, Argentina

Research Site
Buenos Aires, Buenos Aires, Argentina

Research Site
Capital Federal, Buenos Aires, Argentina

Research Site
Ciudad Autonoma de Bs. As., Buenos Aires, Argentina

Research Site
Cordoba, Cordoba, Argentina

Research Site
Corrientes, Corrientes, Argentina

Research Site
Moron, Pcia. de Buenos Aires, Argentina

Research Site
Quilmes, Buenos Aires, Argentina

Research Site
Rosario, Santa Fe, Argentina

Research Site
Salta, Salta, Argentina

Research Site
San Miguel de Tucuman, Argentina

Research Site
Santa Fe, Santa Fe, Argentina

Research Site
Tucuman, Tucuman - Argentina, Argentina

Australia, South Australia
Research Site
Bedford Park, South Australia, Australia

Australia, Australian Capital Territory
Research Site
Bruce, Australian Capital Territory, Australia

Australia, Queensland
Research Site
Chermside, Queensland, Australia

Australia, Victoria
Research Site
Dandenong, Victoria, Australia

Research Site
Geelong, Victoria, Australia

Australia, Queensland
Research Site
Herston, Queensland, Australia

Australia, Victoria
Research Site

Melbourne, Victoria, Australia

Australia, Western Australia

Research Site

Perth, Western Australia, Australia

Australia, Queensland

Research Site

Woolloongabba, Queensland, Australia

Austria

Research Site

Feldkirch, Austria

Research Site

Freistadt, Austria

Research Site

Graz, Austria

Research Site

Innsbruck, Austria

Research Site

Linz, Austria

Research Site

Modling, Austria

Research Site

Villach, Austria

Research Site

Wien, Austria

Belgium

Research Site

Aalst, Belgium, Belgium

Research Site

Bouge, Belgium, Belgium

Research Site

Brasschaat, Belgium, Belgium

Research Site

Brussels (anderlecht), Belgium, Belgium

Research Site

Charleroi, Belgium, Belgium

Research Site

Edegem, Belgium, Belgium

Research Site

Genk, Belgium, Belgium

Research Site

Hasselt, Belgium, Belgium

Research Site

HUY, Belgium, Belgium

Research Site

Liege, Belgium, Belgium

Research Site

Mechelen, Belgium, Belgium

Research Site

MOL, Belgium, Belgium

Research Site

Wilrijk, Belgium, Belgium

Brazil

Research Site

Aracaju, SE, Brazil

Research Site

Belo Horizonte, MG, Brazil

Research Site

Brasilia, DF, Brazil

Research Site

Campinas, Brazil

Research Site

Campo Grande, MS, Brazil

Research Site

Curitiba, PR, Brazil

Research Site

Goiania, GO, Brazil

Research Site

Maceio, AL, Brazil

Research Site

Maringa, PR, Brazil

Research Site

Natal, RN, Brazil

Research Site

Porto Alegre, RS, Brazil

Research Site

Recife, PE, Brazil

Research Site

Rio de Janeiro, RJ, Brazil

Research Site

S.j.rio Preto, SP, Brazil

Research Site

Salvador, BA, Brazil

Research Site

Sao Jose, SC, Brazil

Research Site

Sao Paulo, SP, Brazil

Research Site

Uberlandia, MG, Brazil

Bulgaria

Research Site

Burgas, Bulgaria

Research Site

Dimitrovgrad, Bulgaria

Research Site

Gabrovo, Bulgaria

Research Site

Haskovo, Bulgaria

Research Site

Kazanlak, Bulgaria

Research Site

Pleven, Bulgaria

Research Site

Plovdiv, Bulgaria

Research Site

Ruse, Bulgaria

Research Site

Russe, Bulgaria

Research Site

Smolian, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Varna, Bulgaria

Canada, Ontario

Research Site

Brockville, Ontario, Canada

Canada, Alberta

Research Site

Calgary, Alberta, Canada

Canada, Ontario

Research Site

Cambridge, Ontario, Canada

Canada, British Columbia

Research Site

Campbell River, British Columbia, Canada

Canada, Ontario

Research Site
Cornwall, Ontario, Canada

Canada, Alberta
Research Site
Edmonton, Alberta, Canada

Canada, British Columbia
Research Site
Kelowna, British Columbia, Canada

Canada, Quebec
Research Site
Laval, Quebec, Canada

Canada, Ontario
Research Site
London, Ontario, Canada

Canada, Quebec
Research Site
Montreal, Quebec, Canada

Canada, British Columbia
Research Site
New Westminster, British Columbia, Canada

Canada, Ontario
Research Site
Newmarket, Ontario, Canada

Research Site
Oshawa, Ontario, Canada

Research Site
Ottawa, Ontario, Canada

Canada, British Columbia
Research Site
Penticton, British Columbia, Canada

Canada, Quebec
Research Site
Quebec, Quebec, Canada

Canada, Saskatchewan

Research Site
Regina, Saskatchewan, Canada

Canada, New Brunswick
Research Site
Saint John, New Brunswick, Canada

Canada, Quebec
Research Site
Saint-georges, Quebec, Canada

Canada, Ontario
Research Site
Scarborough, Ontario, Canada

Canada, Quebec
Research Site
Sherbrooke, Quebec, Canada

Canada, Newfoundland and Labrador
Research Site
St. John's, Newfoundland and Labrador, Canada

Canada, British Columbia
Research Site
Surrey, British Columbia, Canada

Canada, Quebec
Research Site
Thetford Mines, Quebec, Canada

Canada, Ontario
Research Site
Toronto, Ontario, Canada

Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada

Research Site
Victoria, British Columbia, Canada

Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada

China, CHINA
Research Site
BEIJING, CHINA, China

China, Sichuan
Research Site
Chengdu, Sichuan, China

China, Guangdong
Research Site
Guangzhou, Guangdong, China

China
Research Site
Hang Zhou, China

China, CHINA
Research Site
SHANGHAI, PUDONG, CHINA, China

China, Liaoning
Research Site
Shenyang, Liaoning, China

Czech Republic
Research Site
Brno, CZ, Czech Republic

Research Site
Hradec Kralove, Czech Republic

Research Site
Jihlava, Czech Republic

Research Site
Kladno, Czech Republic

Research Site
Liberec, Czech Republic

Research Site
Olomouc, Czech Republic

Research Site
Ostrava-poruba, Czech Republic

Research Site
Pardubice, Czech Republic

Research Site
Praha, Czech Republic

Research Site
Slany, Czech Republic

Research Site
Teplice, Czech Republic

Research Site
Usti Nad Labem, Czech Republic

Research Site
Usti Nad Orlici, Czech Republic

Research Site
Zlin, Czech Republic

Research Site
Znojmo, Czech Republic

Denmark
Research Site
Esbjerg, Denmark

Research Site
Fredericia, Denmark

Research Site
Frederiksberg, Denmark

Research Site
Frederikssund, Denmark

Research Site
Glostrup, Denmark

Research Site
Hellerup, Denmark

Research Site
Herlev, Denmark

Research Site
Herning, Denmark

Research Site
Hillerod, Denmark

Research Site
Hjorring, Denmark

Research Site
Holbaek, Denmark

Research Site
Horsens, Denmark

Research Site
Hvidovre, Denmark

Research Site
Kobenhavn, Denmark

Research Site
Koge, Denmark

Research Site
Kolding, Denmark

Research Site
Naestved, Denmark

Research Site
Odense C, Denmark

Research Site
Roskilde, Denmark

Research Site
Silkeborg, Denmark

Research Site
Slagelse, Denmark

Research Site
Viborg, Denmark

Finland

Research Site
Hus (helsinki), Finland

Research Site
Jyvaskyla, Finland

Research Site
Kokkola, Finland, Finland

Research Site
Kuopio, Finland

Research Site
Lahti, Finland

Research Site
Lappeenranta, Finland

Research Site
Pori, Finland

Research Site
Rovaniemi, Finland, Finland

Research Site
Turku, Finland, Finland

France
Research Site
Abbeville, France

Research Site
Allauch, France

Research Site
Arras, France

Research Site
Avignon, France

Research Site
Bayonne, France

Research Site
Besancon, France

Research Site
Brest, France

Research Site
Caen, France

Research Site
Cholet, France

Research Site
Creteil, France

Research Site
Croix, France

Research Site
Dijon, France

Research Site
Douai, France

Research Site
Falaise, France

Research Site
Frejus, France

Research Site
La Rochelle, France

Research Site
Lagny Sur Marne, France

Research Site
Lille, France

Research Site
Limoges, France

Research Site
Lomme, France

Research Site
Marseille, France

Research Site

Nimes, France

Research Site
Orleans, France

Research Site
Paris, France

Research Site
PAU, France

Research Site
Pessac, France

Research Site
Quincy Sous Senart, France

Research Site
Rennes, France

Research Site
Rouen, France

Research Site
Senlis, France

Research Site
Strasbourg, France

Research Site
Toulouse, France

Research Site
Tourcoing, France

Research Site
Valenciennes, France

Georgia
Research Site
Tbilisi, Georgia

Germany
Research Site
Aschaffenburg, Germany

Research Site
Bad Mergentheim, Germany

Research Site
Bad Nauheim, Germany

Research Site
Bad Rothenfelde, Germany

Research Site
Berlin, Germany

Research Site
Bochum, Germany

Research Site
Bonn, Germany

Research Site
Cloppenburg, Germany

Research Site
Coburg, Germany

Research Site
Dortmund, Germany

Research Site
Dresden, Germany

Research Site
Duisburg, Germany

Research Site
Erfurt, Germany

Research Site
Essen, Germany

Research Site
Esslingen, Germany

Research Site
Frankfurt, Germany

Research Site

Gottingen, Germany

Research Site

Greifswald, Germany

Research Site

Halle, Germany

Research Site

Hamburg, Germany

Research Site

Hannover, Germany

Research Site

Heidelberg, Germany

Research Site

Jena, Germany

Research Site

Kiel, Germany

Research Site

Krefeld, Germany

Research Site

Limburg, Germany

Research Site

Lubeck, Germany

Research Site

Mainz, Germany

Research Site

Merseburg, Germany

Research Site

Monchengladbach, Germany

Research Site

Muhlheim An Der Ruhr, Germany

Research Site

Munster, Germany

Research Site
Regensburg, Germany

Research Site
Rostock, Germany

Research Site
ULM, Germany

Research Site
Warendorf, Germany

Research Site
Witten, Germany

Research Site
Wurzburg, Germany

Research Site
Wuppertal, Germany

United Kingdom
Research Site
Airdrie, Lanarkshire, United Kingdom

Research Site
Basingstoke, United Kingdom

Research Site
Belfast, Northern Ireland, United Kingdom

Research Site
Birmingham, United Kingdom

Research Site
Blackpool, United Kingdom

Research Site
Dundee, United Kingdom

Research Site
Edinburgh, United Kingdom

Research Site
Glasgow, United Kingdom

Research Site
Leicester, United Kingdom

Research Site
London, United Kingdom

Research Site
Manchester, United Kingdom

Research Site
Middlesbrough, United Kingdom

Research Site
Poole, United Kingdom

Research Site
Sheffield, United Kingdom

Research Site
Swansea, United Kingdom

Greece
Research Site
Athens, Greece, Greece

Research Site
Heraklion, Crete, Greece

Research Site
Larissa, Greece, Greece

Research Site
Patra, Greece

Research Site
Piraeus, Greece, Greece

Research Site
Thessaloniki, Greece, Greece

Hong Kong
Research Site
Hong Kong, Hong Kong

Hungary
Research Site

Budapest, Hungary

Research Site

Cegled, Hungary

Research Site

Debrecen, Hungary

Research Site

Gyula, Hungary

Research Site

Hodmez-vasarhely, Hungary

Research Site

Kaposvar, Hungary

Research Site

Kecskemet, Hungary

Research Site

Mosonmagyarovar, Hungary

Research Site

Pecs, Hungary

Research Site

Szekesfehervar, Hungary

Research Site

Zalaegerszeg, Hungary

India

Research Site

Ahmedabad, Gujarat, India

Research Site

Bangalore, Karnataka, India

Research Site

Bhopal, Madhya Pradesh, India

Research Site

Bikaner, Rajasthan, India

Research Site

Chennai, Tamilnadu, India

Research Site

Coimbatore, Tamilnadu, India

Research Site

Gandhinagar, Gujarat, India

Research Site

Hyderabad, Andhrapradesh, India

Research Site

Jaipur, Rajasthan, India

Research Site

Kochi, Kerala, India

Research Site

Kolkata, West Bengal, India

Research Site

Mumbai, Maharashtra, India

Research Site

Nagpur, Maharashtra, India

Research Site

New Delhi, Delhi, India

Research Site

Patiala, Punjab, India

Research Site

Thrissur, Kerala, India

Research Site

Vadodara, Gujarat, India

Research Site

Vijayawada, Andhrapradesh, India

Indonesia

Research Site

Bandung, Jawa Barat, Indonesia

Research Site

Denpasar, Bali, Indonesia

Research Site

Jakarta, Indonesia

Research Site

Makassar, Indonesia

Research Site

Semarang, Indonesia

Research Site

Surabaya, Jawa Timur, Indonesia

Israel

Research Site

Afula, Israel

Research Site

Ashkelon, Israel

Research Site

Beer Sheva, Israel

Research Site

Hadera, Israel

Research Site

Haifa, Israel

Research Site

Holon, Israel

Research Site

Jerusalem, Israel

Research Site

Poriya M.p. Lower Galilee, Israel

Research Site

Rehovot, Israel

Research Site

Tel Aviv, Israel

Research Site

Zerifin, Israel

Italy

Research Site

Ancona, AN, Italy

Research Site

Bagno A Ripoli, FI, Italy

Research Site

Bari, BA, Italy

Research Site

Bergamo, BG, Italy

Research Site

Caserta, CE, Italy

Research Site

Catania, CT, Italy

Research Site

Ferrara, FE, Italy

Research Site

Firenze, FI, Italy

Research Site

Foggia, FG, Italy

Research Site

Legnano, MI, Italy

Research Site

Mantova, MN, Italy

Research Site

Massa Carrara, Italy

Research Site

Mestre, VE, Italy

Research Site

Milano, MI, Italy

Research Site

Modena, MO, Italy

Research Site

Monza, MI, Italy

Research Site

Napoli, Italy

Research Site

Novara, NO, Italy

Research Site

Ostia Lido, Roma, Italy

Research Site

Parma, PR, Italy

Research Site

Pavia, PV, Italy

Research Site

Pescara, PE, Italy

Research Site

Roma, Italy

Research Site

Rozzano, MI, Italy

Research Site

San Giovanni Rotondo, FG, Italy

Research Site

Sassari, SS, Italy

Research Site

Treviso, TV, Italy

Research Site

Varese, VA, Italy

Research Site

Verona, VR, Italy

Malaysia

Research Site

Kuala Lumpur, Wilayah Persekutuan, Malaysia

Research Site
Kuching, Sarawak, Malaysia

Research Site
Penang, Malaysia

Mexico
Research Site
Durango, Durango, Mexico

Research Site
Guadalajara, Jalisco, Mexico

Research Site
Mexico, Distrito Federal, Mexico

Research Site
Monterrey, Nuevo Leon, Mexico

Research Site
Puebla, Puebla, Mexico

Research Site
Zapopan, Jalisco, Mexico

Netherlands
Research Site
Alkmaar, Netherlands

Research Site
Almelo, Netherlands

Research Site
Amersfoort, Netherlands

Research Site
Amsterdam, Netherlands

Research Site
Apeldoorn, Netherlands

Research Site
Arnhem, Netherlands

Research Site
Assen, Netherlands

Research Site
Blaricum, Netherlands

Research Site
Breda, Netherlands

Research Site
Capelle Aan Den Ijssel, Netherlands

Research Site
Delft, Netherlands

Research Site
Den Haag, Netherlands

Research Site
Deventer, Netherlands

Research Site
Dordrecht, Netherlands

Research Site
Drachten, Netherlands

Research Site
EDE, Netherlands

Research Site
Eindhoven, Netherlands

Research Site
Goes, Netherlands

Research Site
Gorinchem, Netherlands

Research Site
Gouda, Netherlands

Research Site
Haarlem, Netherlands

Research Site

Hardenberg, Netherlands

Research Site

Harderwijk, Netherlands

Research Site

Heerlen, Netherlands

Research Site

Helmond, Netherlands

Research Site

Hilversum, Netherlands

Research Site

Leeuwarden, Netherlands

Research Site

Maastricht, Netherlands

Research Site

Nieuwegein, Netherlands

Research Site

Nijmegen, Netherlands

Research Site

Rotterdam, Netherlands

Research Site

Spijkenisse, Netherlands

Research Site

Tiel, Netherlands

Research Site

Tilburg, Netherlands

Research Site

Veldhoven, Netherlands

Research Site

Vlaardingen, Netherlands

Norway

Research Site

Arendal, Norway

Research Site
Bergen, Norway

Research Site
Bodo, Norway

Research Site
Drammen, Norway

Research Site
Flekkefjord, Norway

Research Site
Gjovik, Norway

Research Site
Hamar, Norway

Research Site
Kongsberg, Norway

Research Site
Kristiansand, Norway

Research Site
Lillehammer, Norway

Research Site
Nordbyhagen, Norway

Research Site
Notodden, Norway

Research Site
Oslo, Norway

Research Site
RUD, Norway

Research Site
Tromso, Norway

Research Site
Tynset, Norway

Philippines
Research Site
Cebu, Philippines

Research Site
Davao City, Philippines

Research Site
Manila, Philippines

Research Site
Pasig City, Philippines, Philippines

Research Site
Quezon City, Philippines

Poland
Research Site
Bialystok, Poland

Research Site
Bielsko-biala, Poland

Research Site
Bydgoszcz, Poland

Research Site
Bytom, Poland

Research Site
Czestochowa, Poland

Research Site
Elblag, Poland

Research Site
Gda?sk, Poland

Research Site
Gdynia, Poland

Research Site
Grodzisk Mazowiecki, Poland

Research Site
Inowroclaw, Poland

Research Site
Katowice, Poland

Research Site
Krakow, Poland

Research Site
Lodz, Poland

Research Site
Lublin, Poland

Research Site
Olawa, Poland

Research Site
Olsztyn, Poland

Research Site
Opole, Poland

Research Site
Ostrowiec Swietokrzyski, Poland

Research Site
Plock, Poland

Research Site
Poznan, Poland

Research Site
Radom, Poland

Research Site
Szczecin, Poland

Research Site
Tarnow, Poland

Research Site
Torun, Poland

Research Site
Wloclawek, Poland

Research Site

Walbrzych, Poland

Research Site

Warszawa, Poland

Research Site

Wejherowo, Poland

Research Site

Wroclaw, Poland

Research Site

Zamosc, Poland

Portugal

Research Site

Amadora, Portugal

Research Site

Aveiro, Portugal

Research Site

Braga, Portugal

Research Site

Coimbra, Portugal

Research Site

Leiria, Portugal

Research Site

Lisboa, Portugal

Research Site

Penafiel, Portugal

Research Site

Santa Maria Da Feira, Portugal

Research Site

Santarem, Portugal

Research Site

Setubal, Portugal

Research Site

Vila Nova de Gaia, Portugal

Research Site

Vila Real, Portugal

Korea, Republic of

Research Site

Daegu, Korea, Republic of

Research Site

Gwangju, Korea, Republic of

Research Site

Seongnam, Gyeonggido, Korea, Republic of

Research Site

Seoul, Korea, Republic of

Research Site

Suwon, Korea, Republic of

Research Site

Wonju, Korea, Republic of

Romania

Research Site

Braila, Braila, Romania

Research Site

Brasov, Brasov, Romania

Research Site

Bucharest, Romania

Research Site

Buzau, Romania

Research Site

Cluj Napoca, Cluj, Romania

Research Site

Craiova, Romania

Research Site

Iasi, Iasi, Romania

Research Site
Iasi, Romania

Research Site
Pitesti, Arges, Romania

Research Site
Suceava, Romania

Russian Federation
Research Site
Barnaul, Russian Federation

Research Site
Ekaterinburg, Russian Federation

Research Site
Irkutsk, Russian Federation

Research Site
Kaliningrad, Russian Federation

Research Site
Kazan, Russian Federation

Research Site
Kemerovo, Russian Federation

Research Site
Khanty-mansiysk, Khanty-mansiysk Autonomous Dis, Russian Federation

Research Site
Krasnodar, Russian Federation

Research Site
Krasnoyarsk, Russian Federation

Research Site
Moscow, Russian Federation

Research Site
Murmansk, Russian Federation

Research Site
Nizhniy Novgorod, Russian Federation

Research Site
Novosibirsk, Russian Federation

Research Site
Rostov-na-donu, Russian Federation

Research Site
Samara, Russian Federation

Research Site
St. Petersburg, Russian Federation

Research Site
Tomsk, Russian Federation

Research Site
Tyumen, Russian Federation

Research Site
Vladivostok, Russian Federation

Singapore
Research Site
Singapore, Singapore, Singapore

Slovakia
Research Site
Bratislava, Slovakia

Research Site
Kosice, Slovakia

Research Site
Liptovsky Mikulas, Slovakia

Research Site
Martin, Slovakia

Research Site
Nitra, Slovakia

Research Site
Nove Zamky, Slovakia

Research Site
Piestany, Slovakia

Research Site
Ruzomberok, Slovakia

Research Site
Trnava, Slovakia

Research Site
Zilina, Slovakia

South Africa
Research Site
Bloemfontein, Free State, South Africa

Research Site
Cape Town, Cape Town, South Africa

Research Site
Pretoria, South Africa

Research Site
Somerset West, Cape Town, South Africa

Spain
Research Site
Barcelona, Cataluna, Spain

Research Site
Caceres, Extremadura, Spain

Research Site
Gijon, Asturias, Spain

Research Site
Lerida, Cataluna, Spain

Research Site
Madrid, Comunidad de Madrid, Spain

Research Site
Malaga, Andalucia, Spain

Research Site
Palma de Mallorca, Islas Baleares, Spain

Research Site
Sevilla, Andalucia, Spain

Research Site
Terrassa, Cataluna, Spain

Research Site
Valencia, Comunidad Valenciana, Spain

Research Site
Vigo(pontevedra), Galicia, Spain

Sweden
Research Site
Boras, Sweden

Research Site
Eksjo, Sweden

Research Site
Eskilstuna, Sweden

Research Site
Falun, Sweden

Research Site
Halmstad, Sweden

Research Site
Jonkoping, Sweden

Research Site
Kalmar, Sweden

Research Site
Karlskrona, Sweden

Research Site
Lidkoping, Sweden

Research Site
Linkoping, Sweden

Research Site
Ljungby, Sweden

Research Site
Lund, Sweden

Research Site
Ostersund, Sweden

Research Site
Skovde, Sweden

Research Site
Stockholm, Sweden

Research Site
Sundsvall, Sweden

Research Site
Uppsala, Sweden

Research Site
Vasteras, Sweden

Switzerland
Research Site
Bellinzona, Switzerland

Research Site
Bern, Switzerland

Research Site
Geneve, Switzerland

Research Site
Kreuzlingen, Switzerland

Research Site
Lugano, Switzerland

Research Site
Mendrisio, Ticino, Switzerland

Taiwan
Research Site
Kweishan Shiang, Taoyuan Hsien, Taiwan

Research Site
Niao-song-shiang, Kaohsiung, Taiwan

Research Site
Taipei, Taiwan

Thailand
Research Site
Bangkok, Bangkok, Thailand

Research Site
Chiang Mai, Thailand, Thailand

Research Site
Khon Kaen, Thailand, Thailand

Turkey
Research Site
Adana, Turkey

Research Site
Ankara, Sihhiye, Turkey

Research Site
Antalya, Turkey

Research Site
Istanbul, Kartal, Turkey

Research Site
Mersin, Turkey

Ukraine
Research Site
Dnepropetrovsk, Ukraine

Research Site
Donetsk, Ukraine

Research Site
Kharkov, Ukraine

Research Site
Kiev, Ukraine

Research Site
Makiyivka, Ukraine

United States, New Mexico
Research Site
Albuquerque, New Mexico, United States

United States, Texas
Research Site
Amarillo, Texas, United States

United States, South Carolina
Research Site
Anderson, South Carolina, United States

United States, Michigan
Research Site
Ann Arbor, Michigan, United States

United States, Kentucky
Research Site
Ashland, Kentucky, United States

United States, Florida
Research Site
Atlantis, Florida, United States

United States, Maine
Research Site
Auburn, Maine, United States

United States, Texas
Research Site
Austin, Texas, United States

United States, California
Research Site
Bakersfield, California, United States

United States, Maryland
Research Site
Baltimore, Maryland, United States

United States, Maine
Research Site
Bangor, Maine, United States

United States, Oregon
Research Site
Bend, Oregon, United States

United States, Maryland
Research Site

Bethesda, Maryland, United States

United States, California

Research Site

Beverly Hills, California, United States

United States, Alabama

Research Site

Birmingham, Alabama, United States

United States, Massachusetts

Research Site

Boston, Massachusetts, United States

United States, New York

Research Site

Brooklyn, New York, United States

Research Site

Buffalo, New York, United States

United States, California

Research Site

Burbank, California, United States

United States, Vermont

Research Site

Burlington, Vermont, United States

United States, Pennsylvania

Research Site

Camp Hill, Pennsylvania, United States

United States, North Carolina

Research Site

Chapel Hill, North Carolina, United States

United States, South Carolina

Research Site

Charleston, South Carolina, United States

United States, North Carolina

Research Site

Charlotte, North Carolina, United States

United States, Illinois

Research Site
Chicago, Illinois, United States

United States, Ohio
Research Site
Cleveland, Ohio, United States

United States, Missouri
Research Site
Columbia, Missouri, United States

United States, South Carolina
Research Site
Columbia, South Carolina, United States

United States, Ohio
Research Site
Columbus, Ohio, United States

United States, Texas
Research Site
Dallas, Texas, United States

United States, Connecticut
Research Site
Danbury, Connecticut, United States

United States, Pennsylvania
Research Site
Danville, Pennsylvania, United States

United States, Florida
Research Site
Daytona Beach, Florida, United States

United States, Pennsylvania
Research Site
Doylestown, Pennsylvania, United States

United States, Minnesota
Research Site
Duluth, Minnesota, United States

United States, Washington
Research Site
Everett, Washington, United States

United States, Virginia
Research Site
Falls Church, Virginia, United States

United States, Colorado
Research Site
Fort Collins, Colorado, United States

United States, Virginia
Research Site
Fredericksburg, Virginia, United States

United States, Florida
Research Site
Ft. Lauderdale, Florida, United States

United States, Wisconsin
Research Site
Green Bay, Wisconsin, United States

United States, North Carolina
Research Site
Greensboro, North Carolina, United States

United States, South Carolina
Research Site
Greenville, South Carolina, United States

United States, Pennsylvania
Research Site
Harrisburg, Pennsylvania, United States

United States, Connecticut
Research Site
Hartford, Connecticut, United States

United States, California
Research Site
Healdsburg, California, United States

United States, North Carolina
Research Site
High Point, North Carolina, United States

United States, Florida
Research Site

Hollywood, Florida, United States

United States, Texas

Research Site

Houston, Texas, United States

United States, Alabama

Research Site

Huntsville, Alabama, United States

United States, Indiana

Research Site

Indianapolis, Indiana, United States

United States, Iowa

Research Site

Iowa City, Iowa, United States

United States, Tennessee

Research Site

Jackson, Tennessee, United States

United States, Florida

Research Site

Jacksonville, Florida, United States

United States, New York

Research Site

Johnson City, New York, United States

United States, Missouri

Research Site

Joplin, Missouri, United States

United States, Florida

Research Site

Jupiter, Florida, United States

United States, Michigan

Research Site

Kalamazoo, Michigan, United States

United States, Kansas

Research Site

Kansas City, Kansas, United States

United States, Missouri
Research Site
Kansas City, Missouri, United States

United States, Ohio
Research Site
Kettering, Ohio, United States

United States, New York
Research Site
Kingston, New York, United States

United States, Tennessee
Research Site
Knoxville, Tennessee, United States

United States, Pennsylvania
Research Site
Lancaster, Pennsylvania, United States

Research Site
Langhorne, Pennsylvania, United States

United States, Michigan
Research Site
Lansing, Michigan, United States

Research Site
Laper, Michigan, United States

United States, Nebraska
Research Site
Lincoln, Nebraska, United States

United States, California
Research Site
Los Angeles, California, United States

United States, Kentucky
Research Site
Louisville, Kentucky, United States

United States, Texas
Research Site
Lubbock, Texas, United States

United States, Florida
Research Site
Melbourne, Florida, United States

United States, Tennessee
Research Site
Memphis, Tennessee, United States

United States, Florida
Research Site
Miami Beach, Florida, United States

United States, Minnesota
Research Site
Minneapolis, Minnesota, United States

United States, Alabama
Research Site
Mobile, Alabama, United States

United States, West Virginia
Research Site
Morgantown, West Virginia, United States

United States, Indiana
Research Site
Muncie, Indiana, United States

United States, New York
Research Site
New Hartford, New York, United States

Research Site
New York, New York, United States

United States, Delaware
Research Site
Newark, Delaware, United States

United States, New Jersey
Research Site
Newark, New Jersey, United States

United States, Virginia
Research Site
Norfolk, Virginia, United States

United States, New Jersey
Research Site
Oakland, New Jersey, United States

United States, Florida
Research Site
Ocala, Florida, United States

United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States

United States, Kansas
Research Site
Olathe, Kansas, United States

United States, Nebraska
Research Site
Omaha, Nebraska, United States

United States, Florida
Research Site
Orlando, Florida, United States

Research Site
Ormond Beach, Florida, United States

United States, Nebraska
Research Site
Papillion, Nebraska, United States

United States, Illinois
Research Site
Park Ridge, Illinois, United States

United States, New Jersey
Research Site
Paterson, New Jersey, United States

United States, Florida
Research Site
Pensacola, Florida, United States

United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States

Research Site
Pittsburgh, Pennsylvania, United States

United States, Michigan
Research Site
Pontiac, Michigan, United States

United States, Rhode Island
Research Site
Providence, Rhode Island, United States

United States, North Carolina
Research Site
Raleigh, North Carolina, United States

United States, South Dakota
Research Site
Rapid City, South Dakota, United States

United States, New York
Research Site
Rochester, New York, United States

United States, Illinois
Research Site
Rock Island, Illinois, United States

Research Site
Rockford, Illinois, United States

United States, California
Research Site
Roseville, California, United States

United States, Michigan
Research Site
Royal Oak, Michigan, United States

United States, California
Research Site
Sacramento, California, United States

United States, Michigan
Research Site
Saginaw, Michigan, United States

United States, Maryland
Research Site
Salisbury, Maryland, United States

United States, Texas
Research Site
San Antonio, Texas, United States

United States, California
Research Site
San Diego, California, United States

United States, Puerto Rico
Research Site
San Juan, Puerto Rico, United States

United States, Texas
Research Site
San Marcos, Texas, United States

United States, Florida
Research Site
Sarasota, Florida, United States

United States, Pennsylvania
Research Site
Sayre, Pennsylvania, United States

Research Site
Sellersville, Pennsylvania, United States

United States, Louisiana
Research Site
Shreveport, Louisiana, United States

United States, Massachusetts
Research Site
Springfield, Massachusetts, United States

United States, Missouri
Research Site
St Louis, Missouri, United States

United States, Minnesota
Research Site
St Paul, Minnesota, United States

United States, Florida
Research Site
St Petersburg, Florida, United States

United States, New York
Research Site
Syracuse, New York, United States

United States, Washington
Research Site
Tacoma, Washington, United States

United States, California
Research Site
Torrance, California, United States

United States, Michigan
Research Site
Troy, Michigan, United States

United States, Arizona
Research Site
Tucson, Arizona, United States

United States, Oklahoma
Research Site
Tulsa, Oklahoma, United States

United States, Mississippi
Research Site
Tupelo, Mississippi, United States

United States, Texas
Research Site
Tyler, Texas, United States

United States, Indiana
Research Site
Valparaiso, Indiana, United States

United States, Texas
Research Site
Victoria, Texas, United States

United States, Rhode Island
Research Site

Wakefield, Rhode Island, United States

United States, District of Columbia

Research Site

Washington, District of Columbia, United States

United States, Iowa

Research Site

West Des Moines, Iowa, United States

United States, New York

Research Site

Williamsville, New York, United States

United States, Virginia

Research Site

Winchester, Virginia, United States

United States, North Carolina

Research Site

Winston-salem, North Carolina, United States

United States, Pennsylvania

Research Site

Wormleysburg, Pennsylvania, United States

Research Site

York, Pennsylvania, United States

United States, Michigan

Research Site

Ypsilanti, Michigan, United States

United States, Ohio

Research Site

Zanesville, Ohio, United States

References

Citations:

Links:

Study Data/Documents:

Study Results

▶ Participant Flow

Recruitment Details	The first participant was enrolled on 11 October 2006 and the last participant completed the study on 27 February 2009. Study participants were randomized from 855 centers in 43 countries.
Pre-Assignment Details	Participants will already be hospitalized due to their acute condition, and must be enrolled and randomized within 24 hours of the onset of their most recent cardiac ischemic symptoms. Randomization should take place as soon as possible after presentation.

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Overall Study

	TICAGRELOR	CLOPIDOGREL
Started	9333	9291
Completed	9026	9036
Not Completed	307	255
Protocol Violation	7	2
Withdrawal by Subject	296	249
Reason unknown	2	4
Lost to Follow-up	2	0

▶ Baseline Characteristics

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Baseline Measures

	TICAGRELOR	CLOPIDOGREL	Total
Number of Participants	9333	9291	18624
Age, Continuous [units: years] Mean (Standard Deviation)	62.1 (11.21)	62.3 (11.21)	62.2 (22.42)
Gender, Male/Female [units: Participants]			
Female	2655	2633	5288
Male	6678	6658	13336

▶ Outcome Measures

1. Primary Outcome Measure:

Measure Title	Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke
Measure Description	Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke	864	1014

	TICAGRELOR	CLOPIDOGREL
[units: Participants]		

2. Primary Outcome Measure:

Measure Title	Participants With Any Major Bleeding Event
Measure Description	Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9235	9186
Participants With Any Major Bleeding Event [units: Participants]	961	929

3. Secondary Outcome Measure:

Measure Title	Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization
Measure Description	Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months

Safety Issue?	No
---------------	----

Analysis Population Description

The subgroup of patients with intent for invasive management at randomization

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	6732	6676
Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization [units: Participants]	569	668

4. Secondary Outcome Measure:

Measure Title	Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke
Measure Description	Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke [units: Participants]	901	1065

5. Secondary Outcome Measure:

Measure Title	Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.
Measure Description	Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events. [units: Participants]	1290	1456

6. Secondary Outcome Measure:

Measure Title	Participants With MI Event
Measure Description	Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With MI Event [units: Participants]	504	593

7. Secondary Outcome Measure:

Measure Title	Participants With Death From Vascular Causes
Measure Description	Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Death From Vascular Causes [units: Participants]	353	442

8. Secondary Outcome Measure:

Measure Title	Participants With Stroke
Measure Description	Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Stroke [units: Participants]	125	106

9. Secondary Outcome Measure:

Measure Title	Participants With Death From Any Cause
Measure Description	Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time Frame	Randomization up to 12 months
Safety Issue?	No

Analysis Population Description

The population was the full analysis set, which included all randomized patients

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9333	9291
Participants With Death From Any Cause [units: Participants]	399	506

10. Secondary Outcome Measure:

Measure Title	Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding
Measure Description	Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9235	9186
Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding [units: Participants]	362	306

11. Secondary Outcome Measure:

Measure Title	Participants With Major or Minor Bleeding
Measure Description	Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9235	9186
Participants With Major or Minor Bleeding [units: Participants]	1339	1215

12. Secondary Outcome Measure:

Measure Title	Participants With Non-procedural Major Bleeding
Measure Description	Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	9235	9186
Participants With Non-procedural Major Bleeding [units: Participants]	235	180

13. Secondary Outcome Measure:

Measure Title	Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding
Measure Description	Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

Population is all patients who underwent CABG surgery within 7 days of last dose of active study medication.

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	770	814
Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding [units: Participants]	619	654

14. Secondary Outcome Measure:

Measure Title	Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
Measure Description	Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
Time Frame	First dosing up to 12 months
Safety Issue?	Yes

Analysis Population Description

Population is all patients who underwent CABG surgery within 7 days of last dose of active study medication.

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	770	814
Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding	329	341

	TICAGRELOR	CLOPIDOGREL
[units: Participants]		

15. Secondary Outcome Measure:

Measure Title	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization
Measure Description	Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists.
Time Frame	1-week period following randomization
Safety Issue?	Yes

Analysis Population Description

Participants with Holter data in the week after Randomization

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	1451	1415
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization [units: Participants]	84	51

16. Secondary Outcome Measure:

Measure Title	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization
---------------	--

Measure Description	Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists.
Time Frame	1-week period following randomization
Safety Issue?	Yes

Analysis Population Description

Patients who were monitored for one week following randomization (and for one week one month later).

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Measured Values

	TICAGRELOR	CLOPIDOGREL
Number of Participants Analyzed	964	985
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization [units: Participants]	21	16

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	[Not specified]

Reporting Groups

	Description
TICAGRELOR	Ticagrelor 90 mg twice daily dose (BD)
CLOPIDOGREL	Clopidogrel 75 mg once daily dose (ODD)

Serious Adverse Events

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Total	2108/	2117/
Blood and lymphatic system disorders		
Anaemia ^A †	35/9333 (0.38%)	25/9291 (0.27%)
Coagulopathy ^A †	1/9333 (0.01%)	0/9291 (0%)
Disseminated Intravascular Coagulation ^A †	0/9333 (0%)	1/9291 (0.01%)
Granulocytopenia ^A †	1/9333 (0.01%)	0/9291 (0%)
Haemorrhagic Anaemia ^A †	1/9333 (0.01%)	0/9291 (0%)
Hypochromic Anaemia ^A †	1/9333 (0.01%)	0/9291 (0%)
Iron Deficiency Anaemia ^A †	2/9333 (0.02%)	6/9291 (0.06%)
Leukocytosis ^A †	0/9333 (0%)	1/9291 (0.01%)
Leukopenia ^A †	1/9333 (0.01%)	2/9291 (0.02%)
Lymphadenitis ^A †	2/9333 (0.02%)	0/9291 (0%)
Lymphadenopathy ^A †	0/9333 (0%)	1/9291 (0.01%)
Microcytic Anaemia ^A †	1/9333 (0.01%)	2/9291 (0.02%)
Nephrogenic Anaemia ^A †	1/9333 (0.01%)	0/9291 (0%)
Neutropenia ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Normochromic Normocytic Anaemia ^A †	1/9333 (0.01%)	0/9291 (0%)
Pancytopenia ^A †	1/9333 (0.01%)	0/9291 (0%)
Polycythaemia ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Splenic Lesion ^A †	1/9333 (0.01%)	0/9291 (0%)
Spontaneous Haematoma ^A †	2/9333 (0.02%)	0/9291 (0%)
Thrombocythaemia ^A †	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Thrombocytopenia ^A †	7/9333 (0.08%)	8/9291 (0.09%)
Cardiac disorders		
Acute Coronary Syndrome ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Acute Left Ventricular Failure ^A †	3/9333 (0.03%)	2/9291 (0.02%)
Angina Pectoris ^A †	7/9333 (0.08%)	14/9291 (0.15%)
Aortic Valve Stenosis ^A †	2/9333 (0.02%)	3/9291 (0.03%)
Arrhythmia ^A †	8/9333 (0.09%)	4/9291 (0.04%)
Arrhythmia Supraventricular ^A †	1/9333 (0.01%)	2/9291 (0.02%)
Arteriosclerosis Coronary Artery ^A †	0/9333 (0%)	2/9291 (0.02%)
Arteriospasm Coronary ^A †	1/9333 (0.01%)	0/9291 (0%)
Atrial Fibrillation ^A †	70/9333 (0.75%)	68/9291 (0.73%)
Atrial Flutter ^A †	11/9333 (0.12%)	7/9291 (0.08%)
Atrial Rupture ^A †	1/9333 (0.01%)	0/9291 (0%)
Atrial Tachycardia ^A †	1/9333 (0.01%)	3/9291 (0.03%)
Atrioventricular Block ^A †	3/9333 (0.03%)	5/9291 (0.05%)
Atrioventricular Block Complete ^A †	19/9333 (0.2%)	19/9291 (0.2%)
Atrioventricular Block Second Degree ^A †	4/9333 (0.04%)	0/9291 (0%)
Bradycardia ^A †	26/9333 (0.28%)	31/9291 (0.33%)
Bradyarrhythmia ^A †	3/9333 (0.03%)	3/9291 (0.03%)
Bundle Branch Block ^A †	0/9333 (0%)	1/9291 (0.01%)
Bundle Branch Block Left ^A †	0/9333 (0%)	1/9291 (0.01%)
Cardiac Aneurysm ^A †	1/9333 (0.01%)	3/9291 (0.03%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Cardiac Arrest ^{A †}	38/9333 (0.41%)	44/9291 (0.47%)
Cardiac Asthma ^{A †}	3/9333 (0.03%)	6/9291 (0.06%)
Cardiac Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Cardiac Failure ^{A †}	122/9333 (1.31%)	129/9291 (1.39%)
Cardiac Failure Acute ^{A †}	18/9333 (0.19%)	18/9291 (0.19%)
Cardiac Failure Chronic ^{A †}	5/9333 (0.05%)	2/9291 (0.02%)
Cardiac Failure Congestive ^{A †}	51/9333 (0.55%)	46/9291 (0.5%)
Cardiac Tamponade ^{A †}	11/9333 (0.12%)	16/9291 (0.17%)
Cardiac Valve Disease ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cardio-Respiratory Arrest ^{A †}	8/9333 (0.09%)	12/9291 (0.13%)
Cardiogenic Shock ^{A †}	60/9333 (0.64%)	66/9291 (0.71%)
Cardiomyopathy ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Cardiopulmonary Failure ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Cardiovascular Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Chordae Tendinae Rupture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Coronary Artery Disease ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Coronary Artery Dissection ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Coronary Artery Insufficiency ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Coronary Artery Occlusion ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Coronary Artery Perforation ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Coronary Artery Stenosis ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Coronary Artery Thrombosis ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Cyanosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Dissecting Coronary Artery Aneurysm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Dressler's Syndrome ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Electromechanical Dissociation ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Extrasystoles ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Hypertrophic Cardiomyopathy ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Interventricular Septum Rupture ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Intracardiac Thrombus ^{A †}	13/9333 (0.14%)	15/9291 (0.16%)
Ischaemic Cardiomyopathy ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Left Ventricular Dysfunction ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Left Ventricular Failure ^{A †}	10/9333 (0.11%)	5/9291 (0.05%)
Long Qt Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Low Cardiac Output Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Mitral Valve Incompetence ^{A †}	4/9333 (0.04%)	6/9291 (0.06%)
Myocardial Infarction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Myocardial Ischaemia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Myocardial Rupture ^{A †}	2/9333 (0.02%)	4/9291 (0.04%)
Myocarditis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Nodal Rhythm ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Palpitations ^{A †}	8/9333 (0.09%)	7/9291 (0.08%)
Papillary Muscle Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Papillary Muscle Rupture ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Pericardial Effusion ^{A †}	9/9333 (0.1%)	10/9291 (0.11%)
Pericardial Haemorrhage ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Pericarditis ^{A †}	6/9333 (0.06%)	8/9291 (0.09%)
Right Ventricular Failure ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Sick Sinus Syndrome ^{A †}	7/9333 (0.08%)	2/9291 (0.02%)
Sinus Arrest ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Sinus Bradycardia ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)
Stress Cardiomyopathy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Supraventricular Tachycardia ^{A †}	8/9333 (0.09%)	8/9291 (0.09%)
Tachyarrhythmia ^{A †}	4/9333 (0.04%)	4/9291 (0.04%)
Tachycardia ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)
Torsade De Pointes ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ventricle Rupture ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Ventricular Arrhythmia ^{A †}	3/9333 (0.03%)	6/9291 (0.06%)
Ventricular Dysfunction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ventricular Extrasystoles ^{A †}	6/9333 (0.06%)	1/9291 (0.01%)
Ventricular Fibrillation ^{A †}	48/9333 (0.51%)	64/9291 (0.69%)
Ventricular Tachyarrhythmia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ventricular Tachycardia ^{A †}	29/9333 (0.31%)	33/9291 (0.36%)
Congenital, familial and genetic disorders		
Carbohydrate Metabolism Disorder ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Diverticulitis Meckel's ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Gastrointestinal Angiodysplasia Haemorrhagic ^A †	0/9333 (0%)	1/9291 (0.01%)
Haemorrhagic Arteriovenous Malformation ^A †	1/9333 (0.01%)	0/9291 (0%)
Ventricular Septal Defect ^A †	0/9333 (0%)	1/9291 (0.01%)
Ear and labyrinth disorders		
Deafness ^A †	1/9333 (0.01%)	0/9291 (0%)
Hypoacusis ^A †	2/9333 (0.02%)	0/9291 (0%)
Sudden Hearing Loss ^A †	0/9333 (0%)	1/9291 (0.01%)
Tinnitus ^A †	1/9333 (0.01%)	0/9291 (0%)
Vertigo ^A †	8/9333 (0.09%)	5/9291 (0.05%)
Vertigo Positional ^A †	1/9333 (0.01%)	0/9291 (0%)
Vestibular Neuronitis ^A †	1/9333 (0.01%)	3/9291 (0.03%)
Endocrine disorders		
Goitre ^A †	0/9333 (0%)	1/9291 (0.01%)
Hyperthyroidism ^A †	2/9333 (0.02%)	2/9291 (0.02%)
Pituitary-Dependent Cushing's Syndrome ^A †	1/9333 (0.01%)	0/9291 (0%)
Thyrotoxic Crisis ^A †	0/9333 (0%)	1/9291 (0.01%)
Eye disorders		
Amaurosis ^A †	1/9333 (0.01%)	0/9291 (0%)
Amaurosis Fugax ^A †	0/9333 (0%)	1/9291 (0.01%)
Blindness ^A †	1/9333 (0.01%)	0/9291 (0%)
Cataract ^A †	3/9333 (0.03%)	2/9291 (0.02%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Cataract Nuclear ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Chorioretinitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Conjunctival Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diabetic Retinopathy ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diplopia ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Eye Haemorrhage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Glaucoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Macular Degeneration ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Posterior Capsule Opacification ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Retinal Artery Embolism ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Retinal Detachment ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Visual Impairment ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Vitreous Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastrointestinal disorders		
Abdominal Discomfort ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Abdominal Hernia Obstructive ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Abdominal Pain ^{A †}	21/9333 (0.23%)	10/9291 (0.11%)
Abdominal Pain Upper ^{A †}	9/9333 (0.1%)	15/9291 (0.16%)
Anal Fistula ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Anal Haemorrhage ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Appendicitis Perforated ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Ascites ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Colitis Ischaemic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Colitis Ulcerative ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Colonic Polyp ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Constipation ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Dental Caries ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Diarrhoea ^{A †}	12/9333 (0.13%)	9/9291 (0.1%)
Diarrhoea Haemorrhagic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diverticular Perforation ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Diverticulitis Intestinal Haemorrhagic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diverticulum ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Diverticulum Intestinal ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Diverticulum Intestinal Haemorrhagic ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Duodenal Ulcer ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Duodenal Ulcer Haemorrhage ^{A †}	10/9333 (0.11%)	2/9291 (0.02%)
Duodenitis ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Dyspepsia ^{A †}	6/9333 (0.06%)	5/9291 (0.05%)
Dysphagia ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Enteritis ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Enterocolitis Haemorrhagic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Epigastric Discomfort ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Erosive Oesophagitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Faecal Incontinence ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Faeces Discoloured ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Food Poisoning ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Gastric Disorder ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Gastric Haemorrhage ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Gastric Ulcer ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Gastric Ulcer Haemorrhage ^{A †}	11/9333 (0.12%)	6/9291 (0.06%)
Gastritis ^{A †}	8/9333 (0.09%)	9/9291 (0.1%)
Gastritis Atrophic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Gastritis Erosive ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Gastritis Haemorrhagic ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Gastroduodenal Haemorrhage ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Gastrointestinal Disorder ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Gastrointestinal Haemorrhage ^{A †}	45/9333 (0.48%)	42/9291 (0.45%)
Gastrointestinal Necrosis ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Gastrointestinal Pain ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastrointestinal Ulcer Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastrooesophageal Reflux Disease ^{A †}	4/9333 (0.04%)	7/9291 (0.08%)
Gingival Bleeding ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gingivitis Ulcerative ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Haematemesis ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Haematochezia ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Haemorrhagic Erosive Gastritis ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Haemorrhoidal Haemorrhage ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Haemorrhoids ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Hiatus Hernia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ileus Paralytic ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Inguinal Hernia ^{A †}	4/9333 (0.04%)	4/9291 (0.04%)
Inguinal Hernia Strangulated ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Intestinal Haemorrhage ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Intestinal Ischaemia ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Intestinal Obstruction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Intestinal Polyp ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Intra-Abdominal Haemorrhage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Large Intestine Perforation ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Lower Gastrointestinal Haemorrhage ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)
Mallory-Weiss Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Melaena ^{A †}	10/9333 (0.11%)	3/9291 (0.03%)
Mesenteric Artery Embolism ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Mouth Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Nausea ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Oesophageal Food Impaction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Oesophageal Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Oesophageal Pain ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Oesophageal Varices Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Oesophagitis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Oesophagitis Haemorrhagic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pancreatic Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pancreatic Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pancreatitis ^{A †}	4/9333 (0.04%)	5/9291 (0.05%)
Pancreatitis Acute ^{A †}	5/9333 (0.05%)	1/9291 (0.01%)
Pancreatitis Chronic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Peptic Ulcer ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Peptic Ulcer Haemorrhage ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Peritonitis ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Pneumoperitoneum ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Polyp Colorectal ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Proctitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Rectal Haemorrhage ^{A †}	7/9333 (0.08%)	6/9291 (0.06%)
Rectal Polyp ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Reflux Oesophagitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Retroperitoneal Fibrosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Retroperitoneal Haematoma ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Retroperitoneal Haemorrhage ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Small Intestinal Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Small Intestinal Obstruction ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Small Intestinal Perforation ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Stomach Mass ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Subileus ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thrombosis Mesenteric Vessel ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tongue Oedema ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Toothache ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Upper Gastrointestinal Haemorrhage ^{A †}	9/9333 (0.1%)	7/9291 (0.08%)
Volvulus ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Vomiting ^{A †}	10/9333 (0.11%)	4/9291 (0.04%)
General disorders		
Accidental Death ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Alcohol Interaction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Application Site Inflammation ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Asthenia ^{A †}	6/9333 (0.06%)	4/9291 (0.04%)
Cardiac Death ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Catheter Site Haemorrhage ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Chest Discomfort ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Chest Pain ^{A †}	54/9333 (0.58%)	63/9291 (0.68%)
Death ^{A †}	21/9333 (0.23%)	31/9291 (0.33%)
Discomfort ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Fatigue ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Foaming At Mouth ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gait Disturbance ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
General Physical Health Deterioration ^{A †}	1/9333 (0.01%)	5/9291 (0.05%)
Generalised Oedema ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hernia ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hypothermia ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Impaired Healing ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)
Inflammation ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Inflammation Of Wound ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Injection Site Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Injection Site Swelling ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Malaise ^{A †}	6/9333 (0.06%)	3/9291 (0.03%)
Multi-Organ Failure ^{A †}	9/9333 (0.1%)	9/9291 (0.1%)
Non-Cardiac Chest Pain ^{A †}	101/9333 (1.08%)	103/9291 (1.11%)
Oedema Peripheral ^{A †}	4/9333 (0.04%)	1/9291 (0.01%)
Pain ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pelvic Mass ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Puncture Site Haemorrhage ^{A †}	4/9333 (0.04%)	1/9291 (0.01%)
Pyrexia ^{A †}	10/9333 (0.11%)	5/9291 (0.05%)
Sudden Cardiac Death ^{A †}	14/9333 (0.15%)	25/9291 (0.27%)
Sudden Death ^{A †}	17/9333 (0.18%)	27/9291 (0.29%)
Systemic Inflammatory Response Syndrome ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Ulcer Haemorrhage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Unevaluable Event ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vessel Puncture Site Haematoma ^{A †}	8/9333 (0.09%)	12/9291 (0.13%)
Vessel Puncture Site Haemorrhage ^{A †}	9/9333 (0.1%)	6/9291 (0.06%)
Hepatobiliary disorders		
Bile Duct Obstruction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Bile Duct Stone ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Biliary Colic ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Cholangitis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Cholecystitis ^{A †}	7/9333 (0.08%)	10/9291 (0.11%)
Cholecystitis Acute ^{A †}	5/9333 (0.05%)	7/9291 (0.08%)
Cholecystitis Chronic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cholelithiasis ^{A †}	9/9333 (0.1%)	9/9291 (0.1%)
Cholestasis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gallbladder Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gallbladder Necrosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hepatic Cirrhosis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Hepatic Failure ^{A †}	2/9333 (0.02%)	4/9291 (0.04%)
Hepatic Function Abnormal ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hepatitis Toxic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hepatocellular Injury ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Ischaemic Hepatitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Jaundice ^{A †}	0/9333 (0%)	2/9291 (0.02%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Liver Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Immune system disorders		
Allergy To Arthropod Bite ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Anaphylactic Reaction ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Anaphylactic Shock ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Contrast Media Allergy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Drug Hypersensitivity ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Hypersensitivity ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Infections and infestations		
Abdominal Abscess ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Abdominal Wall Infection ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Abscess Limb ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Acquired Immunodeficiency Syndrome ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Acute Sinusitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Acute Tonsillitis ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Anal Abscess ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Appendicitis ^{A †}	6/9333 (0.06%)	2/9291 (0.02%)
Arthritis Bacterial ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Arthritis Infective ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Bacteraemia ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Bacterial Infection ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Breast Abscess ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Bronchiectasis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Bronchitis ^{A †}	13/9333 (0.14%)	15/9291 (0.16%)
Bronchitis Viral ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Bronchopneumonia ^{A †}	10/9333 (0.11%)	4/9291 (0.04%)
Catheter Related Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Catheter Site Infection ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Cellulitis ^{A †}	9/9333 (0.1%)	9/9291 (0.1%)
Cholecystitis Infective ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Clostridium Difficile Colitis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Cystitis ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Dengue Fever ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Device Related Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diarrhoea Infectious ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diverticulitis ^{A †}	7/9333 (0.08%)	8/9291 (0.09%)
Endocarditis ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Endometritis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Enterococcal Infection ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Enterocolitis Infectious ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Erysipelas ^{A †}	4/9333 (0.04%)	4/9291 (0.04%)
Febrile Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gangrene ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Gastric Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastroenteritis ^{A †}	17/9333 (0.18%)	11/9291 (0.12%)
Gastroenteritis Caliciviral ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Gastroenteritis Rotavirus ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Gastroenteritis Salmonella ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastroenteritis Viral ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Gastrointestinal Infection ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Groin Abscess ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Groin Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Haematoma Infection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Helicobacter Gastritis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Hepatitis Viral ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Herpes Zoster ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Histoplasmosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Impetigo ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Incision Site Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Incision Site Infection ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Infected Skin Ulcer ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Infection ^{A †}	1/9333 (0.01%)	5/9291 (0.05%)
Infective Exacerbation Of Chronic Obstructive Airways Disease ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Infective Tenosynovitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Inguinal Hernia Gangrenous ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Injection Site Cellulitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Intervertebral Discitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Laryngitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Liver Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lobar Pneumonia ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Localised Infection ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Lower Respiratory Tract Infection ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Lung Infection ^{A †}	5/9333 (0.05%)	4/9291 (0.04%)
Lyme Disease ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Mediastinitis ^{A †}	11/9333 (0.12%)	4/9291 (0.04%)
Meningitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Necrotising Fasciitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Orchitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Osteomyelitis ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Pancreatic Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Perineal Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pharyngitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pneumococcal Sepsis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pneumonia ^{A †}	69/9333 (0.74%)	95/9291 (1.02%)
Pneumonia Staphylococcal ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Post Procedural Cellulitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Post Procedural Infection ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Post Procedural Sepsis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Postoperative Wound Infection ^{A †}	9/9333 (0.1%)	3/9291 (0.03%)
Pulmonary Sepsis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pulmonary Tuberculosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Puncture Site Abscess ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Puncture Site Infection ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pyelonephritis ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Pyelonephritis Acute ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Pyothorax ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Rectal Abscess ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Renal Abscess ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Respiratory Tract Infection ^{A †}	9/9333 (0.1%)	5/9291 (0.05%)
Retroperitoneal Abscess ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Sepsis ^{A †}	17/9333 (0.18%)	27/9291 (0.29%)
Septic Shock ^{A †}	5/9333 (0.05%)	10/9291 (0.11%)
Sinusitis ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Skin Infection ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Staphylococcal Infection ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Staphylococcal Mediastinitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Staphylococcal Sepsis ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Sterinitis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Subcutaneous Abscess ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Syphilis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Tooth Abscess ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Tooth Infection ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tracheitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Tracheobronchitis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Upper Respiratory Tract Infection ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Urinary Tract Infection ^{A †}	25/9333 (0.27%)	19/9291 (0.2%)
Urosepsis ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Viral Myocarditis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Viral Pericarditis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Wound Infection ^{A †}	7/9333 (0.08%)	8/9291 (0.09%)
Injury, poisoning and procedural complications		
Alanine Aminotransferase Increased ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Alcohol Poisoning ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Anaemia Postoperative ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Angiogram ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Ankle Fracture ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Antiphospholipid Antibodies ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Aspartate Aminotransferase Increased ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)
Blood Creatine Phosphokinase Increased ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Blood Creatinine Increased ^A †	1/9333 (0.01%)	0/9291 (0%)
Blood Glucose Increased ^A †	2/9333 (0.02%)	1/9291 (0.01%)
Blood Potassium Decreased ^A †	1/9333 (0.01%)	0/9291 (0%)
Blood Potassium Increased ^A †	0/9333 (0%)	2/9291 (0.02%)
Blood Pressure Decreased ^A †	1/9333 (0.01%)	0/9291 (0%)
Blood Pressure Increased ^A †	3/9333 (0.03%)	3/9291 (0.03%)
Blood Sodium Decreased ^A †	1/9333 (0.01%)	0/9291 (0%)
Blood Urine Present ^A †	1/9333 (0.01%)	0/9291 (0%)
Body Temperature Increased ^A †	2/9333 (0.02%)	0/9291 (0%)
Brain Contusion ^A †	1/9333 (0.01%)	0/9291 (0%)
C-Reactive Protein Increased ^A †	1/9333 (0.01%)	0/9291 (0%)
Cardiac Enzymes Increased ^A †	1/9333 (0.01%)	0/9291 (0%)
Cardiac Pacemaker Malfunction ^A †	1/9333 (0.01%)	0/9291 (0%)
Cardiac Procedure Complication ^A †	1/9333 (0.01%)	0/9291 (0%)
Cardiac Stress Test Abnormal ^A †	1/9333 (0.01%)	0/9291 (0%)
Chest Injury ^A †	1/9333 (0.01%)	0/9291 (0%)
Clavicle Fracture ^A †	0/9333 (0%)	2/9291 (0.02%)
Concussion ^A †	2/9333 (0.02%)	2/9291 (0.02%)
Contrast Media Reaction ^A †	0/9333 (0%)	1/9291 (0.01%)
Contusion ^A †	0/9333 (0%)	1/9291 (0.01%)
Coronary Artery Reocclusion ^A †	0/9333 (0%)	1/9291 (0.01%)
Coronary Artery Restenosis ^A †	4/9333 (0.04%)	9/9291 (0.1%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Device Breakage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Device Dislocation ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Device Malfunction ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Device Migration ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Electrocardiogram Qt Prolonged ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Electrocardiogram T Wave Inversion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Facial Bones Fracture ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Fall ^{A †}	1/9333 (0.01%)	5/9291 (0.05%)
Fat Embolism ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Femoral Neck Fracture ^{A †}	3/9333 (0.03%)	5/9291 (0.05%)
Femur Fracture ^{A †}	3/9333 (0.03%)	7/9291 (0.08%)
Fibrin D Dimer Increased ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Foot Fracture ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Forearm Fracture ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Fracture ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Fractured Ischium ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Graft Thrombosis ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Haemoglobin Decreased ^{A †}	6/9333 (0.06%)	8/9291 (0.09%)
Hand Fracture ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Head Injury ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Heart Rate Increased ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Hepatic Enzyme Increased ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Hip Fracture ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Humerus Fracture ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Implantable Defibrillator Malfunction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
In-Stent Arterial Restenosis ^{A †}	10/9333 (0.11%)	12/9291 (0.13%)
In-Stent Coronary Artery Restenosis ^{A †}	35/9333 (0.38%)	25/9291 (0.27%)
Incision Site Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Incisional Hernia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Injury ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
International Normalised Ratio Increased ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Intraocular Pressure Increased ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Joint Dislocation ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Joint Injury ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Joint Sprain ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ligament Rupture ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Limb Injury ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Limb Traumatic Amputation ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Liver Function Test Abnormal ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Lower Limb Fracture ^{A †}	0/9333 (0%)	4/9291 (0.04%)
Lumbar Vertebral Fracture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Meniscus Lesion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Occult Blood ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Open Wound ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Operative Haemorrhage ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Overdose ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Pancreatic Enzymes Increased ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pelvic Fracture ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Platelet Count Decreased ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Post Procedural Complication ^{A †}	4/9333 (0.04%)	4/9291 (0.04%)
Post Procedural Haematoma ^{A †}	7/9333 (0.08%)	1/9291 (0.01%)
Post Procedural Haematuria ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Post Procedural Haemorrhage ^{A †}	56/9333 (0.6%)	47/9291 (0.51%)
Postoperative Thoracic Procedure Complication ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Postoperative Thrombosis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Postoperative Wound Complication ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Postpericardiotomy Syndrome ^{A †}	5/9333 (0.05%)	2/9291 (0.02%)
Procedural Complication ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Procedural Hypotension ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Procedural Pain ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Prostatic Specific Antigen Abnormal ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Prostatic Specific Antigen Increased ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Radius Fracture ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Renal Injury ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Rib Fracture ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Road Traffic Accident ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Scrotal Haematoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Spinal Compression Fracture ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Stent Occlusion ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Subcutaneous Haematoma ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Subdural Haematoma ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Suture Rupture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tendon Rupture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Thermal Burn ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thrombosis In Device ^{A †}	35/9333 (0.38%)	57/9291 (0.61%)
Tibia Fracture ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Tracheal Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tracheal Obstruction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Transfusion Reaction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Traumatic Haemorrhage ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Traumatic Intracranial Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Troponin Increased ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Ulna Fracture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Upper Limb Fracture ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Urinary Bladder Rupture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Urinary Retention Postoperative ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vascular Graft Occlusion ^{A †}	2/9333 (0.02%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Vascular Procedure Complication ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vascular Pseudoaneurysm ^{A †}	15/9333 (0.16%)	23/9291 (0.25%)
Vascular Pseudoaneurysm Ruptured ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vertebral Injury ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Weaning Failure ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Weight Decreased ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Wound Complication ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Wound Dehiscence ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Wrist Fracture ^{A †}	4/9333 (0.04%)	0/9291 (0%)
Metabolism and nutrition disorders		
Anorexia ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Dehydration ^{A †}	11/9333 (0.12%)	5/9291 (0.05%)
Diabetes Mellitus ^{A †}	6/9333 (0.06%)	7/9291 (0.08%)
Diabetes Mellitus Inadequate Control ^{A †}	3/9333 (0.03%)	9/9291 (0.1%)
Diabetic Foot ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diabetic Ketoacidosis ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Electrolyte Depletion ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Failure To Thrive ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Fluid Overload ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Gout ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Hyperglycaemia ^{A †}	7/9333 (0.08%)	2/9291 (0.02%)
Hyperkalaemia ^{A †}	1/9333 (0.01%)	4/9291 (0.04%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Hyperosmolar State ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Hypoglycaemia ^{A †}	11/9333 (0.12%)	8/9291 (0.09%)
Hypokalaemia ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Hyponatraemia ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Hypovolaemia ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Ketoacidosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Metabolic Acidosis ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Metabolic Disorder ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Metabolic Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Type 2 Diabetes Mellitus ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Musculoskeletal and connective tissue disorders		
Arthralgia ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Arthritis ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Back Pain ^{A †}	3/9333 (0.03%)	6/9291 (0.06%)
Bone Pain ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Bursitis ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Chondropathy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Costochondritis ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Dupuytren's Contracture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Gouty Arthritis ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Groin Pain ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Intervertebral Disc Degeneration ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Intervertebral Disc Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Intervertebral Disc Protrusion ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Joint Swelling ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lumbar Spinal Stenosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Monarthritis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Muscle Tightness ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Muscular Weakness ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Musculoskeletal Chest Pain ^{A †}	15/9333 (0.16%)	16/9291 (0.17%)
Musculoskeletal Pain ^{A †}	5/9333 (0.05%)	4/9291 (0.04%)
Myalgia ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Myalgia Intercostal ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Myositis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Neck Pain ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Osteoarthritis ^{A †}	7/9333 (0.08%)	5/9291 (0.05%)
Osteochondrosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Osteolysis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Osteoporosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pain In Extremity ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Pain In Jaw ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pathological Fracture ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Polyarthritis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Polymyalgia Rheumatica ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Polymyositis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Rhabdomyolysis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Rheumatoid Arthritis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Spinal Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Spinal Osteoarthritis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Wrist Deformity ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Abdominal Neoplasm ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Acute Myeloid Leukaemia ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Adenocarcinoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Adenocarcinoma Pancreas ^{A †}	0/9333 (0%)	1/9291 (0.01%)
B-Cell Lymphoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Benign Duodenal Neoplasm ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Benign Neoplasm Of Skin ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Benign Uterine Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Bladder Cancer ^{A †}	2/9333 (0.02%)	6/9291 (0.06%)
Bladder Cancer Recurrent ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Bladder Neoplasm ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Bladder Transitional Cell Carcinoma ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Bone Neoplasm Malignant ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Brain Cancer Metastatic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Brain Neoplasm ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Breast Cancer ^{A †}	3/9333 (0.03%)	9/9291 (0.1%)
Breast Cancer Metastatic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Bronchial Carcinoma ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Bronchial Neoplasm ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Carcinoid Tumour Of The Caecum ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Carcinoid Tumour Of The Duodenum ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Chronic Leukaemia ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Chronic Lymphocytic Leukaemia ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Colon Adenoma ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Colon Cancer ^{A †}	10/9333 (0.11%)	3/9291 (0.03%)
Colon Neoplasm ^{A †}	1/9333 (0.01%)	5/9291 (0.05%)
Colorectal Cancer ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Endometrial Cancer ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastric Cancer ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Gastric Neoplasm ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Gastrointestinal Carcinoma ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Gastrointestinal Neoplasm ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Glioblastoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Haemangioma Of Liver ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Hepatic Cancer Metastatic ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Hepatic Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Intestinal Adenocarcinoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Laryngeal Cancer ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Lip And/Or Oral Cavity Cancer ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Lung Adenocarcinoma ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Lung Cancer Metastatic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lung Neoplasm ^{A †}	7/9333 (0.08%)	5/9291 (0.05%)
Lung Neoplasm Malignant ^{A †}	6/9333 (0.06%)	10/9291 (0.11%)
Lymphangiosis Carcinomatosa ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Lymphocytic Lymphoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lymphoma ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Malignant Melanoma ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Malignant Pleural Effusion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Meningioma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Metastases To Bone ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Metastases To Central Nervous System ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Metastases To Liver ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Metastases To Lung ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Metastases To Lymph Nodes ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Metastatic Neoplasm ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Myelodysplastic Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Neoplasm Malignant ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Neoplasm Prostate ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Nipple Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Oesophageal Carcinoma ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Ovarian Cancer ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Pancreatic Carcinoma Recurrent ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pleural Mesothelioma ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Polycythaemia Vera ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Prostate Cancer ^{A †}	6/9333 (0.06%)	8/9291 (0.09%)
Prostate Cancer Metastatic ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Prostate Cancer Recurrent ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Prostatic Adenoma ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Rectal Cancer ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Rectal Cancer Metastatic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal Cancer ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Renal Cancer Metastatic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Renal Neoplasm ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Retroperitoneal Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Small Cell Lung Cancer Metastatic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Small Cell Lung Cancer Stage Unspecified ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Spinal Cord Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Squamous Cell Carcinoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Testis Cancer ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thyroid Adenoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thyroid Cancer Metastatic ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thyroid Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tongue Neoplasm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Transitional Cell Carcinoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Uterine Leiomyoma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Nervous system disorders		
Altered State Of Consciousness ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Balance Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Brain Oedema ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Brain Stem Infarction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Brain Stem Ischaemia ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Brain Stem Stroke ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Carotid Artery Disease ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Carotid Artery Occlusion ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Carotid Artery Stenosis ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Carotid Artery Thrombosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Carotid Sinus Syndrome ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Central Nervous System Lesion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cerebellar Infarction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cerebral Atrophy ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Cerebral Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cerebral Haemorrhage ^{A †}	9/9333 (0.1%)	3/9291 (0.03%)
Cerebral Infarction ^{A †}	7/9333 (0.08%)	8/9291 (0.09%)
Cerebral Ischaemia ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Cerebrovascular Accident ^{A †}	75/9333 (0.8%)	50/9291 (0.54%)
Cerebrovascular Disorder ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Cerebrovascular Insufficiency ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Cervicobrachial Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Cognitive Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Complex Partial Seizures ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Convulsion ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Dementia ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Depressed Level Of Consciousness ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Diabetic Hyperosmolar Coma ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Diabetic Neuropathy ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Dizziness ^{A †}	13/9333 (0.14%)	7/9291 (0.08%)
Dysphasia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Embolic Cerebral Infarction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Encephalitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Encephalopathy ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Epilepsy ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Extrapyramidal Disorder ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Facial Paresis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Febrile Convulsion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Haemorrhage Intracranial ^{A †}	5/9333 (0.05%)	2/9291 (0.02%)
Haemorrhagic Cerebral Infarction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Haemorrhagic Stroke ^{A †}	6/9333 (0.06%)	7/9291 (0.08%)
Headache ^{A †}	6/9333 (0.06%)	3/9291 (0.03%)
Hemiparesis ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Hepatic Encephalopathy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Hypoaesthesia ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Hypotonia ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Hypoxic Encephalopathy ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Intracranial Haematoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ischaemic Cerebral Infarction ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Ischaemic Stroke ^{A †}	20/9333 (0.21%)	28/9291 (0.3%)
Lacunar Infarction ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Loss Of Consciousness ^{A †}	4/9333 (0.04%)	2/9291 (0.02%)
Lumbar Radiculopathy ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Mental Impairment ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Migraine ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Myelitis Transverse ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Narcolepsy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Neuralgia ^{A †}	2/9333 (0.02%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Paraesthesia ^A †	5/9333 (0.05%)	4/9291 (0.04%)
Parkinson's Disease ^A †	1/9333 (0.01%)	4/9291 (0.04%)
Parkinsonism ^A †	0/9333 (0%)	1/9291 (0.01%)
Partial Seizures ^A †	2/9333 (0.02%)	0/9291 (0%)
Phrenic Nerve Paralysis ^A †	1/9333 (0.01%)	0/9291 (0%)
Post Herpetic Neuralgia ^A †	0/9333 (0%)	1/9291 (0.01%)
Presyncope ^A †	8/9333 (0.09%)	2/9291 (0.02%)
Progressive Supranuclear Palsy ^A †	0/9333 (0%)	1/9291 (0.01%)
Psychomotor Hyperactivity ^A †	0/9333 (0%)	1/9291 (0.01%)
Sciatica ^A †	0/9333 (0%)	1/9291 (0.01%)
Speech Disorder ^A †	1/9333 (0.01%)	0/9291 (0%)
Spinal Cord Compression ^A †	0/9333 (0%)	1/9291 (0.01%)
Spinal Cord Disorder ^A †	1/9333 (0.01%)	0/9291 (0%)
Subarachnoid Haemorrhage ^A †	4/9333 (0.04%)	2/9291 (0.02%)
Syncope ^A †	32/9333 (0.34%)	30/9291 (0.32%)
Syncope Vasovagal ^A †	4/9333 (0.04%)	2/9291 (0.02%)
Thalamus Haemorrhage ^A †	1/9333 (0.01%)	0/9291 (0%)
Thrombotic Stroke ^A †	1/9333 (0.01%)	0/9291 (0%)
Transient Ischaemic Attack ^A †	19/9333 (0.2%)	23/9291 (0.25%)
Vascular Encephalopathy ^A †	1/9333 (0.01%)	0/9291 (0%)
Vertebrobasilar Insufficiency ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Vith Nerve Paralysis ^A †	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Vocal Cord Paresis ^A †	1/9333 (0.01%)	0/9291 (0%)
Psychiatric disorders		
Acute Stress Disorder ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Agitation ^A †	1/9333 (0.01%)	0/9291 (0%)
Alcohol Abuse ^A †	1/9333 (0.01%)	0/9291 (0%)
Alcoholism ^A †	0/9333 (0%)	1/9291 (0.01%)
Anxiety ^A †	9/9333 (0.1%)	6/9291 (0.06%)
Anxiety Disorder ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Completed Suicide ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Confusional State ^A †	4/9333 (0.04%)	2/9291 (0.02%)
Delirium ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Depression ^A †	9/9333 (0.1%)	7/9291 (0.08%)
Drug Abuse ^A †	0/9333 (0%)	1/9291 (0.01%)
Insomnia ^A †	1/9333 (0.01%)	0/9291 (0%)
Mania ^A †	1/9333 (0.01%)	0/9291 (0%)
Mental Disorder ^A †	0/9333 (0%)	1/9291 (0.01%)
Nervousness ^A †	0/9333 (0%)	1/9291 (0.01%)
Neurosis ^A †	0/9333 (0%)	1/9291 (0.01%)
Panic Attack ^A †	1/9333 (0.01%)	0/9291 (0%)
Post-Traumatic Amnestic Disorder ^A †	1/9333 (0.01%)	0/9291 (0%)
Psychotic Disorder ^A †	1/9333 (0.01%)	0/9291 (0%)
Schizophrenia, Paranoid Type ^A †	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Sleep Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Suicidal Ideation ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Suicide Attempt ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Tension ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Transient Psychosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal and urinary disorders		
Anuria ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Azotaemia ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Bladder Mass ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Bladder Prolapse ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Bladder Tamponade ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Calculus Bladder ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Calculus Ureteric ^{A †}	2/9333 (0.02%)	4/9291 (0.04%)
Calculus Urethral ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Calculus Urinary ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Cystitis Haemorrhagic ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Cystitis Noninfective ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Dysuria ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Glomerulonephritis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Glomerulonephritis Membranous ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Glomerulonephritis Minimal Lesion ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Haematuria ^{A †}	15/9333 (0.16%)	10/9291 (0.11%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Haemorrhage Urinary Tract ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Hydronephrosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Nephritis Autoimmune ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Nephrolithiasis ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Nephropathy Toxic ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Nephrotic Syndrome ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Obstructive Uropathy ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Oliguria ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal Artery Stenosis ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Renal Artery Thrombosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal Colic ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Renal Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal Failure ^{A †}	25/9333 (0.27%)	24/9291 (0.26%)
Renal Failure Acute ^{A †}	34/9333 (0.36%)	25/9291 (0.27%)
Renal Failure Chronic ^{A †}	7/9333 (0.08%)	7/9291 (0.08%)
Renal Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Renal Impairment ^{A †}	5/9333 (0.05%)	4/9291 (0.04%)
Renal Mass ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Urethral Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Urinary Bladder Haemorrhage ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Urinary Bladder Polyp ^{A †}	0/9333 (0%)	2/9291 (0.02%)
Urinary Incontinence ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Urinary Retention ^{A †}	3/9333 (0.03%)	7/9291 (0.08%)
Urinary Tract Obstruction ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Reproductive system and breast disorders		
Balanitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Benign Prostatic Hyperplasia ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Cervical Dysplasia ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Epididymitis ^{A †}	3/9333 (0.03%)	1/9291 (0.01%)
Menometrorrhagia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Ovarian Cyst ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Prostatic Haemorrhage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Prostatism ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Prostatitis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Spermatocele ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Uterine Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vaginal Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Respiratory, thoracic and mediastinal disorders		
Acute Pulmonary Oedema ^{A †}	20/9333 (0.21%)	32/9291 (0.34%)
Acute Respiratory Distress Syndrome ^{A †}	4/9333 (0.04%)	3/9291 (0.03%)
Acute Respiratory Failure ^{A †}	5/9333 (0.05%)	6/9291 (0.06%)
Alveolitis Fibrosing ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Apnoea ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Aspiration ^{A †}	0/9333 (0%)	3/9291 (0.03%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Asthma ^A †	5/9333 (0.05%)	3/9291 (0.03%)
Atelectasis ^A †	1/9333 (0.01%)	0/9291 (0%)
Brain Hypoxia ^A †	0/9333 (0%)	1/9291 (0.01%)
Bronchial Haemorrhage ^A †	1/9333 (0.01%)	0/9291 (0%)
Bronchial Obstruction ^A †	1/9333 (0.01%)	0/9291 (0%)
Bronchitis Chronic ^A †	1/9333 (0.01%)	0/9291 (0%)
Bronchospasm ^A †	2/9333 (0.02%)	1/9291 (0.01%)
Chronic Obstructive Pulmonary Disease ^A †	22/9333 (0.24%)	17/9291 (0.18%)
Cough ^A †	3/9333 (0.03%)	0/9291 (0%)
Dyspnoea ^A †	75/9333 (0.8%)	50/9291 (0.54%)
Dyspnoea Exertional ^A †	3/9333 (0.03%)	2/9291 (0.02%)
Dyspnoea Paroxysmal Nocturnal ^A †	0/9333 (0%)	1/9291 (0.01%)
Emphysema ^A †	1/9333 (0.01%)	0/9291 (0%)
Epistaxis ^A †	15/9333 (0.16%)	9/9291 (0.1%)
Haemoptysis ^A †	7/9333 (0.08%)	8/9291 (0.09%)
Haemothorax ^A †	0/9333 (0%)	3/9291 (0.03%)
Hydrothorax ^A †	2/9333 (0.02%)	5/9291 (0.05%)
Hyperventilation ^A †	2/9333 (0.02%)	1/9291 (0.01%)
Hypoxia ^A †	0/9333 (0%)	1/9291 (0.01%)
Interstitial Lung Disease ^A †	0/9333 (0%)	1/9291 (0.01%)
Laryngeal Leukoplakia ^A †	1/9333 (0.01%)	0/9291 (0%)
Laryngeal Oedema ^A †	1/9333 (0.01%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Laryngeal Stenosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Laryngospasm ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lower Respiratory Tract Inflammation ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lung Consolidation ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Lung Disorder ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Mediastinal Haematoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Mediastinal Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Nasal Polyps ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Nocturnal Dyspnoea ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pleural Effusion ^{A †}	21/9333 (0.23%)	19/9291 (0.2%)
Pleurisy ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Pleuritic Pain ^{A †}	0/9333 (0%)	3/9291 (0.03%)
Pneumonia Aspiration ^{A †}	3/9333 (0.03%)	6/9291 (0.06%)
Pneumonitis ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Pneumothorax ^{A †}	3/9333 (0.03%)	9/9291 (0.1%)
Pulmonary Alveolar Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pulmonary Congestion ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Pulmonary Embolism ^{A †}	31/9333 (0.33%)	20/9291 (0.22%)
Pulmonary Fibrosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Pulmonary Haematoma ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pulmonary Haemorrhage ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Pulmonary Mass ^{A †}	3/9333 (0.03%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Pulmonary Oedema ^{A †}	33/9333 (0.35%)	53/9291 (0.57%)
Respiratory Arrest ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Respiratory Distress ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Respiratory Failure ^{A †}	16/9333 (0.17%)	16/9291 (0.17%)
Respiratory Tract Haemorrhage ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Rhinorrhoea ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Systemic Sclerosis Pulmonary ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tachypnoea ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thoracic Haemorrhage ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Tonsillar Disorder ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Tracheal Stenosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Vocal Cord Polyp ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Wegener's Granulomatosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Wheezing ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Skin and subcutaneous tissue disorders		
Alopecia ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Angioedema ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Blister ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Decubitus Ulcer ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Dermatitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Dermatitis Allergic ^{A †}	1/9333 (0.01%)	6/9291 (0.06%)
Dermatomyositis ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Dry Gangrene ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Eczema Nummular ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Erythema ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Hyperhidrosis ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Hypoaesthesia Facial ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Increased Tendency To Bruise ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Leukocytoclastic Vasculitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Pruritus ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Pruritus Generalised ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Rash ^{A †}	4/9333 (0.04%)	3/9291 (0.03%)
Rash Erythematous ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Rash Generalised ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Seborrhoeic Dermatitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Skin Inflammation ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Skin Necrosis ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Skin Ulcer ^{A †}	3/9333 (0.03%)	0/9291 (0%)
Urticaria ^{A †}	3/9333 (0.03%)	4/9291 (0.04%)
Wound Haemorrhage ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Surgical and medical procedures		
Cardiac Pacemaker Insertion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Coronary Artery Bypass ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Implantable Defibrillator Insertion ^{A †}	0/9333 (0%)	1/9291 (0.01%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Leg Amputation ^A †	1/9333 (0.01%)	0/9291 (0%)
Thoracic Cavity Drainage ^A †	0/9333 (0%)	1/9291 (0.01%)
Vascular disorders		
Accelerated Hypertension ^A †	1/9333 (0.01%)	5/9291 (0.05%)
Aneurysm ^A †	0/9333 (0%)	1/9291 (0.01%)
Aneurysm Ruptured ^A †	1/9333 (0.01%)	0/9291 (0%)
Angiodysplasia ^A †	1/9333 (0.01%)	0/9291 (0%)
Aortic Aneurysm ^A †	0/9333 (0%)	7/9291 (0.08%)
Aortic Aneurysm Rupture ^A †	2/9333 (0.02%)	1/9291 (0.01%)
Aortic Dilatation ^A †	1/9333 (0.01%)	1/9291 (0.01%)
Aortic Dissection ^A †	2/9333 (0.02%)	4/9291 (0.04%)
Aortic Stenosis ^A †	0/9333 (0%)	3/9291 (0.03%)
Arterial Disorder ^A †	1/9333 (0.01%)	0/9291 (0%)
Arterial Occlusive Disease ^A †	2/9333 (0.02%)	2/9291 (0.02%)
Arterial Rupture ^A †	0/9333 (0%)	1/9291 (0.01%)
Arterial Thrombosis ^A †	1/9333 (0.01%)	4/9291 (0.04%)
Arterial Thrombosis Limb ^A †	5/9333 (0.05%)	4/9291 (0.04%)
Arteriosclerosis ^A †	3/9333 (0.03%)	3/9291 (0.03%)
Arteriosclerosis Obliterans ^A †	1/9333 (0.01%)	2/9291 (0.02%)
Arteriovenous Fistula ^A †	2/9333 (0.02%)	1/9291 (0.01%)
Arteritis ^A †	0/9333 (0%)	1/9291 (0.01%)
Artery Dissection ^A †	2/9333 (0.02%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Bleeding Varicose Vein ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Blood Pressure Inadequately Controlled ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Cardiovascular Insufficiency ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Circulatory Collapse ^{A †}	4/9333 (0.04%)	0/9291 (0%)
Deep Vein Thrombosis ^{A †}	6/9333 (0.06%)	6/9291 (0.06%)
Embolism ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Embolism Venous ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Extremity Necrosis ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Femoral Arterial Stenosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Femoral Artery Aneurysm ^{A †}	1/9333 (0.01%)	3/9291 (0.03%)
Femoral Artery Occlusion ^{A †}	2/9333 (0.02%)	2/9291 (0.02%)
Haematoma ^{A †}	3/9333 (0.03%)	8/9291 (0.09%)
Haemodynamic Instability ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Haemorrhage ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Hypertension ^{A †}	17/9333 (0.18%)	24/9291 (0.26%)
Hypertensive Crisis ^{A †}	7/9333 (0.08%)	12/9291 (0.13%)
Hypertensive Emergency ^{A †}	3/9333 (0.03%)	3/9291 (0.03%)
Hypotension ^{A †}	18/9333 (0.19%)	21/9291 (0.23%)
Hypovolaemic Shock ^{A †}	3/9333 (0.03%)	2/9291 (0.02%)
Iliac Artery Occlusion ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Iliac Artery Stenosis ^{A †}	1/9333 (0.01%)	2/9291 (0.02%)
Iliac Artery Thrombosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Intermittent Claudication ^{A †}	6/9333 (0.06%)	6/9291 (0.06%)
Leriche Syndrome ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Orthostatic Hypotension ^{A †}	4/9333 (0.04%)	3/9291 (0.03%)
Peripheral Arterial Occlusive Disease ^{A †}	4/9333 (0.04%)	5/9291 (0.05%)
Peripheral Artery Aneurysm ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Peripheral Artery Dissection ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Peripheral Embolism ^{A †}	1/9333 (0.01%)	1/9291 (0.01%)
Peripheral Ischaemia ^{A †}	10/9333 (0.11%)	7/9291 (0.08%)
Peripheral Vascular Disorder ^{A †}	5/9333 (0.05%)	3/9291 (0.03%)
Phlebitis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Reperfusion Injury ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Shock ^{A †}	7/9333 (0.08%)	3/9291 (0.03%)
Shock Haemorrhagic ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Subclavian Artery Stenosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Subclavian Artery Thrombosis ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Subclavian Vein Thrombosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Thrombophlebitis ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Thrombophlebitis Superficial ^{A †}	2/9333 (0.02%)	1/9291 (0.01%)
Thrombosis ^{A †}	2/9333 (0.02%)	0/9291 (0%)
Vascular Occlusion ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vasculitis ^{A †}	1/9333 (0.01%)	0/9291 (0%)
Vena Cava Thrombosis ^{A †}	1/9333 (0.01%)	0/9291 (0%)

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Venous Insufficiency ^{A †}	0/9333 (0%)	1/9291 (0.01%)
Venous Thrombosis ^{A †}	2/9333 (0.02%)	3/9291 (0.03%)
Venous Thrombosis Limb ^{A †}	0/9333 (0%)	2/9291 (0.02%)

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA 10.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	TICAGRELOR	CLOPIDOGREL
	Affected/At Risk (%)	Affected/At Risk (%)
Total	2278/	1665/
Nervous system disorders		
Headache ^{A †}	621/9333 (6.65%)	565/9291 (6.08%)
Respiratory, thoracic and mediastinal disorders		
Cough ^{A †}	490/9333 (5.25%)	467/9291 (5.03%)
Dyspnoea ^{A †}	1106/9333 (11.85%)	623/9291 (6.71%)
Epistaxis ^{A †}	566/9333 (6.06%)	317/9291 (3.41%)

† Indicates events were collected by systematic assessment.

A Term from vocabulary, MedDRA 10.0

► Limitations and Caveats

[Not specified]

► More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

An Investigator agrees to provide a copy of the publication to AstraZeneca (AZ) for review at least 60 days in advance of submission for publication. Investigators in multicenter (MC) studies agree to postpone MC publications until the earlier of the date of the first AZ-authorized MC publication or a period up to 18 months from study completion at all sites.

Results Point of Contact:

Name/Official Title: Gerard Lynch

Organization: AstraZeneca

Phone:

Email: aztrial_results_posting@astrazeneca.com